We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity...
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®...
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping...
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the...
Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp...
L'Organisme canadien de réglementation des investissements permet la reprise de la négociation - MDNA Canada NewsWire TORONTO, le 26 avril 2024 TORONTO, le 26 avril 2024 /CNW/...
Canadian Investment Regulatory Organization Trade Resumption - MDNA Canada NewsWire TORONTO, April 26, 2024 TORONTO, April 26, 2024 /CNW/ - Trading resumes in: Company: Medicenna Therapeutics...
Suspension de la négociation par l'Organisme canadien de réglementation des investissements - MDNA Canada NewsWire TORONTO, le 26 avril 2024 TORONTO, le 26 avril 2024 /CNW/...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1 | -4.87804878049 | 2.05 | 2.17 | 1.86 | 55679 | 1.99413848 | CS |
4 | -0.08 | -3.94088669951 | 2.03 | 2.25 | 1.77 | 77582 | 1.97806484 | CS |
12 | -0.3 | -13.3333333333 | 2.25 | 2.98 | 1.64 | 111886 | 2.27403438 | CS |
26 | 1.495 | 328.571428571 | 0.455 | 2.98 | 0.41 | 138225 | 1.82787978 | CS |
52 | 1.39 | 248.214285714 | 0.56 | 2.98 | 0.215 | 102327 | 1.36644248 | CS |
156 | -0.97 | -33.2191780822 | 2.92 | 3.67 | 0.215 | 62664 | 1.5473976 | CS |
260 | 0.59 | 43.3823529412 | 1.36 | 7.25 | 0.215 | 73542 | 2.72749029 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions